Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Hager Investment Management Services LLC

Hager Investment Management Services LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,345 shares of the pharmaceutical company’s stock after selling 66 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 1.4% of Hager Investment Management Services LLC’s holdings, making the stock its 25th largest holding. Hager Investment Management Services LLC’s holdings in Vertex Pharmaceuticals were worth $2,380,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Advisor OS LLC boosted its stake in Vertex Pharmaceuticals by 4.4% during the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after buying an additional 23 shares during the last quarter. Avidian Wealth Enterprises LLC raised its position in Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock valued at $594,000 after purchasing an additional 25 shares during the period. Strategic Blueprint LLC raised its position in Vertex Pharmaceuticals by 1.7% in the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock valued at $726,000 after purchasing an additional 25 shares during the period. Newman Dignan & Sheerar Inc. raised its position in Vertex Pharmaceuticals by 3.3% in the second quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after purchasing an additional 25 shares during the period. Finally, Glenview Trust co raised its position in Vertex Pharmaceuticals by 0.4% in the first quarter. Glenview Trust co now owns 6,920 shares of the pharmaceutical company’s stock valued at $3,355,000 after purchasing an additional 30 shares during the period. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of research analyst reports. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a research report on Wednesday, August 6th. Raymond James Financial initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They issued a “market perform” rating on the stock. Wall Street Zen downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price objective for the company from $458.00 to $456.00 in a report on Thursday, September 25th. Finally, HC Wainwright cut their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $494.43.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $421.15 on Thursday. The stock has a 50-day simple moving average of $395.83 and a 200-day simple moving average of $440.97. The stock has a market cap of $107.98 billion, a P/E ratio of 30.10 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.